Reforgene ranks in the 2021 healthcare Top 15 Best Emerging Enterprise award

On May 26, 2022, CHC Medical Consulting, together with CITIC Securities, officially released the "2021 Annual China Healthcare Industry Investment and Financing Honor List". As an authoritative list in the healthcare field from a third-party perspective, the China Healthcare Industry Investment and Financing Honor List has been held since 2018. Based on a review of the current state of investment and financing development in the healthcare industry and upholding the principles of fairness, impartiality and objective neutrality, it is produced through data statistics, horizontal comparison and full-dimensional analysis, aiming to commend the value contributors in the healthcare field in 2021, set industry benchmarks, and explore the hard strength behind quality investment institutions, listed companies and innovative enterprises.

Reforgene was selected into the 2021 Healthcare Best Emerging Enterprise Award TOP15, demonstrating its independent innovation, rapid growth and unlimited potential. Reforgene is a leading innovative gene medicine enterprise in China, driven by gene editing technology and dedicated to the birth of novel medicines. It currently has pipeline programs in genetic diseases, complex diseases and oncology, among which its beta-thalassemia gene editing therapy has achieved globally leading clinical progress.

About CHC Medical Consulting

CHC Medical Consulting is a value platform focused on the healthcare industry, committed to providing online and offline professional services for domestic and international medical enterprises, investment institutions and medical industrial parks through years of in-depth research and extensive cooperation in the medical professional field and its accumulation in the capital market, helping medical practitioners obtain the latest industry information and promote cooperation and exchange.